Products
Co-DX PCR Home Testing Platform
PCR Home Covid-19 Test Kit
Co-DX Box
Diagnostic Solutions
Diagnostics Logix Smart Abc
Diagnostics Logix Smart COVID 19
Diagnostics Logix Smart MTB
Diagnostics Logix Smart SARS-CoV-2 DS
Diagnostics Logix Smart SARS-CoV-2 RdRpE
Diagnostics Logix Smart ZDC
Diagnostics Logix Smart Zika
Research Solutions
Research Logix Smart Abc RUO
Research Logix Smart COVID-19 RUO
Research Logix Smart Monkeypox RUO
Research Logix Smart Mpox (2-Gene) RUO
Research Logix Smart SARS-CoV-2 DS RUO
Research Logix Smart SARS-CoV-2 RUO
Maverick Blue® Nucleic Acid Stain
Vector Control Solutions
Vector Smart NAM-e
Vector Smart NAM-w
Vector Smart VZDC
Industries
Industry At Home
Industry Healthcare
Industry Laboratory
Industry Business Enterprise
Industry Vector Control
Technology
Real-Time PCR
Multiplexing
Co-Primers
About
Our Story
CoSara
Leadership
Scientific Advisory Board
Newsroom
Awards and Grants
Contact Us
Feedback
Resources
All Resources
Blog
News Articles
Publications
Events and Webcasts
Skip to content
123 Main Street, New York, NY 10001
123-456-7890
Top Navigation with Mega Menu
Products
Co-Dx™ PCR Pro™ Instrument
PCR Home COVID-19 Test
Co-Dx Box™
LABORATORY SOLUTIONS
Diagnostic Solutions
Logix Smart® ABC
Logix Smart® COVID-19 (FDA EUA)
Logix Smart® MTB
Logix Smart® SARS-CoV-2 (RdRp/E)
Logix Smart® SARS-CoV-2 (DS)
Logix Smart® ZDC (ZIKV-DENV-CHIKV)
Logix Smart® Zika Virus (ZIKV)
Research Solutions
Logix Smart® ABC (RUO)
Logix Smart® COVID-19 (RUO)
Logix Smart® Mpox (RUO)
Logix Smart® Mpox 2-Gene (RUO)
Logix Smart® SARS-CoV-2 (RUO)
Logix Smart® SARS-CoV-2 DS (RUO)
Maverick Blue® Nucleic Acid Stain
Vector Control Solutions
Vector Smart™ NAM-e
Vector Smart™ NAM-w
Vector Smart™ VZDC
Industries
Healthcare Professionals
Enterprise/Businesses
Laboratory Professionals
At Home Consumers
Vector Control Professionals
Technology
Real-Time PCR
Multiplexing
Co-Primers™
About
Our Story
CoSara
Leadership
Scientific Advisory Board
Awards and Grants
Contact
Feedback
Resources
All Resources
Blog
News Articles
Publications
Events and Webcasts
Search
Search
Search
Search
Investor Relations
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Feb 4, 2026
Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Jan 12, 2026
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
Dec 30, 2025
Co-Diagnostics Announces Reverse Stock Split
Dec 29, 2025
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Dec 18, 2025
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Dec 17, 2025
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
Dec 9, 2025
Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
Dec 8, 2025
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Nov 20, 2025
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Nov 18, 2025
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
Nov 13, 2025
Co-Diagnostics Reports Third Quarter 2025 Financial Results
Nov 12, 2025
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
Nov 5, 2025
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
Nov 3, 2025
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Oct 31, 2025
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
Oct 30, 2025
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
Oct 29, 2025
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 28, 2025
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 27, 2025
Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East
Oct 22, 2025
Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
Oct 16, 2025
Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
Oct 13, 2025
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
Sep 30, 2025
Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30
Sep 18, 2025
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Sep 17, 2025
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
14
»
Join Our Newsletter
Receive our latest blog posts directly in your inbox!
Your email
Sign up now